Lactobacillus Crispatus for Vaginal Health

Research suggests that Lactobacillus crispatus plays a central role in vaginal health, with a substantial body of evidence — including reviews, mechanistic laboratory studies, and two randomized controlled trials — indicating that this species helps protect against bacterial vaginosis, yeast infections, sexually transmitted infections, and pregnancy complications through multiple pathways, including lactic acid production, immune modulation via surface-layer proteins, and the release of targeted antimicrobial compounds such as hydroxyisocaproate. Studies indicate that L. crispatus dominance in the vaginal microbiome is consistently associated with lower inflammation, reduced pathogen burden, and more favorable reproductive outcomes, and clinical trials suggest that probiotic formulations containing this species — delivered either orally or vaginally — can reduce symptoms and improve microbiome balance in women with bacterial vaginosis or vulvovaginal candidiasis, though one trial found that oral probiotics did not significantly improve cure rates when added to standard antibiotic treatment. The evidence is not entirely uniform, however: findings are mixed regarding whether probiotics confer meaningful clinical benefit beyond microbiome-level changes, and emerging genomic research has identified specific L. crispatus gene variants associated with increased cervical dysplasia risk, underscoring that strain-level differences within this species may matter and that not all L. crispatus strains are functionally identical. Overall, the research is promising but still evolving, and most mechanistic studies have been conducted in laboratory settings, meaning translation to consistent clinical benefit in diverse populations remains an active area of investigation.